NASDAQ
4.57USD
-0.03 (-0.65%)
We have scored 14 news catalysts on MiMedx Group, Inc. (MDXG) over the past 12 months. The biggest single-day move next to one of them came May 21, 2026, when MDXG closed −4.7%: “INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG”. Coverage across the window leans negative (average ticker sentiment −0.41). Most of the impact sits in price momentum and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
666.1M
P/E
—
EPS
—
Beta
1.42
52W range
3.03-7.97
Day range
4.51–4.71
Open
4.67
Prev close
4.60
Volume
995.8K
Avg volume
1.3M
Dividend
0.00
IPO
2008-02-12
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about MiMedx Group, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for MDXG: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue. This exclusive and patented processing technique incorporates both aseptic procedures and a final sterilization step, ensuring product safety and efficacy. Among its offerings is EpiFix, a semi-permeable membrane designed to act as a protective barrier, effectively treating persistent wounds such as diabetic foot ulcers, venous leg ulcers, and pressure sores. Another key product is AmnioFix, a protective, semi-permeable allograft made from dehydrated human amnion/chorion membrane, utilized to aid post-surgical recovery. EpiCord and AmnioCord, both derived from dehydrated human umbilical cord, function as allografts that foster a protective healing environment and are applied in both advanced wound care and surgical recovery contexts. AMNIOBURN is also a semi-permeable protective allograft specifically developed for managing partial and full-thickness burn injuries. Its flagship product, mdHACM, is a micronized, powdered version of AMNIOFIX. These products predominantly find use in healthcare sectors like wound management, burn treatment, surgical procedures, and non-operative sports medicine. Additionally, the company supplies allografts for dental uses to other manufacturers on an original equipment manufacturer (OEM) basis. Distribution of its products primarily occurs within the United States, facilitated by its own sales teams, independent agents, and various independent distributors. MiMedx Group, Inc.'s main office is located in Marietta, Georgia.
